Chronic Kidney Disease and COVID-19 Mortality: A Systematic Review and Meta-Analysis
View/ Open
Issue Date
2021-05-31Author
Thomas, Preston
Publisher
University of Kansas
Format
74 pages
Type
Thesis
Degree Level
M.S.
Discipline
Population Health
Rights
Copyright held by the author.
Metadata
Show full item recordAbstract
Introduction: The outbreak of the coronavirus disease 2019 (COVID-19) has caused a pandemic and continues to a play a role in the increasing mortality rates among high-risk populations such as individuals with comorbidities like cardiovascular disease, diabetes, and chronic kidney disease (CKD). In patients diagnosed with CKD, infections are a significant factor which contribute to mortality second only to cardiovascular complications. The aim of this review was to conduct a systematic review and meta-analyses to evaluate the mortality associated with CKD in patients diagnosed with COVID-19 and to stratify the effect estimates by sample size, progression of CKD (stages III-V only), or end-stage kidney disease (ESKD).Methods: We searched the most updated and highest quality systematic reviews for primary articles and subsequently conducted a comprehensive systematic search of the Embase, PubMed, Epistemonikos, Cochrane, and Google Scholar databases from Sep 1st, 2020 to Jan 10th, 2021 for published articles. We also performed a search of the LiTCOVID, MEDRXIV, and SSRN databases for preprints of unpublished studies from Jan 1st, 2020 to Jan 5th, 2021. Results: We identified 75 studies that reported effect estimates for mortality for patients diagnosed with COVID-19 and CKD. Mortality was significantly higher among patients with CKD and COVID-19 than their counterparts without CKD (HR 1.57, 95% CI [1.42, 1.73], P < 0.00001; OR 1.86, 95% CI [1.64, 2.11], P < 0.00001; RR 1.74, 95% CI [1.13, 2.69], P = 0.01). The subgroup analyses investigating the effect of CKD stage (III-V) revealed increased mortality (HR 2.02 (95% CI [1.39, 2.94], P = 0.0002) as well as those analyzing the effect of ESKD (HR 1.92, 95% CI [0.96, 3.81], P = 0.06; OR 1.44, 95% CI [1.15, 1.81], P = 0.002). Regardless of study sample size, the trend of increased mortality in patients with CKD and COVID-19 was apparent. Conclusion: Our findings demonstrated that patients diagnosed with CKD or ESKD have an increased risk of mortality and that COVID-19 management strategies as well as policies should prioritize patients with CKD or ESKD.
Collections
- Theses [3943]
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.